Article Sidebar
Views PDF: 97
Value of mri with gadoxetic acid (primovist) for diagnosing hepatocellular carcinoma
Main Article Content
Abstract
Aim: Evaluate the value of MRI with Gd-EOB-DTPA (Primovist) in the detection of HCC comparison with the pathological results
Methods: Descriptive cross-sectional research, performed on 28 patients consist of 2 groups: Group I includes 18 patients with HCC and group II includes 10 non-HCC patients (7 patients with focal nodular hyperplasia. 3 patients with liver metastasis). The patients whose liver lesion were detected on diagnostic imaging modalities undergone MRI with hepatiobillial specific contrast agent Gd-EOB-DTPA (Primovist). Thereafter, definite diagnosis was based on histopathological results of biopsy or surgery.
Results: Hepatobiillial phase hypointense was the most sensitive diagnostic criteria of HCC(94.4%), however, specificity is only 70%. For liver cancer diagnosing, arterial enhancement followed by washout on portal venous or late phase had the sensitivity, negative predictive value and diagnostic accuracy were 61.1%, 58.8% and 75%, respectively. When combining with hepatobillial phase hypointense, these values increased to 72.2%, 67.7%, and 82.1%, respectively; while, the specificity and positive predictive values were unchanged.
Conclusion: Hepatobiillial phase hypointense is a good diagnostic criteria on detection of HCC than differential diagnosis with other hepatic lesions. The addition of hepatobiillial phase on MRI with Gd-EOB-DTPA (Primovist) increases the likelihood of detecting HCC lesions
Article Details
References
2. Le VQ, Nguyen VH, Nguyen VH, et al. Epidemiological Characteristics of Advanced Hepatocellular Carcinoma in the Northern Region of Vietnam. Cancer Control. 019;26(1):1-6. doi:10.1177/1073274819862793
3. Bray F, Ferlay J, Soerjomataram I, et al. cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018;68(6):394-424. doi:10.3322/caac.21492
4. Nguyen VTT, Law MG, Dore GJ. An enormous hepatitis B virus-related liver disease burden projected in Vietnam by 2025. Liver International. 2008;28(4):525-531. doi:10.1111/j.1478-3231.2007.01646.x
5. Huy LM, Hà HTN, Oanh NT. Tương quan giữa AFP huyết thanh và các yếu tố tiên lượng khác trong carcinoma tế bào gan. 2010:36-42.
6. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264-1273.e1. doi:10.1053/j.gastro.2011.12.061
7. International Consensus Group for Hepatocellular NeoplasiaThe International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology. 2009;49(2):658-664. doi:10.1002/hep.22709
8. Kutami R, Nakashima Y, Nakashima O, Shiota K, Kojiro M. Pathomorphologic study on the mechanism of fatty change in small hepatocellular carcinoma of humans. Journal of Hepatology. 2000;33(2):282-289. doi:10.1016/S0168-8278(00)80369-4
9. Mri CT, Core L. American College of Radiology: Core LI-RADS CT/MRI Diagnostic Table.
10. Ng MMT, Fan ST, Glas FRCS. Tumor Encapsulation in Hepatocellular Carcinoma A Pathologic Study of 189 Cases. 1991:45-49.
11. Cho ES, Choi JY. MRI features of hepatocellular carcinoma related to biologic behavior. Korean Journal of Radiology. 2015;16(3):449-464. doi:10.3348/kjr.2015.16.3.449
12. Huy HQ. Nghiên cứu vai trò cộng hưởng từ trong chẩn đoán và đánh giá kết quả điều trị ung thư biểu mô tế bào gan bằng phương pháp nút mạch hóa dầu. Luận án tiến sĩ - Đại học Y Hà Nội. 2008:1-50.
13. Piana G, Trinquart L, Meskine N, et al. New MR imaging criteria with a diffusion-weighted sequence for the diagnosis of hepatocellular carcinoma in chronic liver diseases. Journal of Hepatology. 2011;55(1):126-132. doi:10.1016/j.jhep.2010.10.023
14. Kim YK, Kim CS, Han YM, et al. Detection of liver malignancy with gadoxetic acid-enhanced MRI: Is addition of diffusion-weighted MRI beneficial? Clinical Radiology. 2011;66(6):489-496. doi:10.1016/j.crad.2010.09.007
15. Choi SH, Byun JH, Lim YS, et al. Diagnostic criteria for hepatocellular carcinoma ≤3 cm with hepatocyte-specific contrast-enhanced magnetic resonance imaging. Journal of Hepatology. 2016;64(5):1099-1107. doi:10.1016/j.jhep.2016.01.018
16. Golfieri R, Grazioli L, Orlando E, et al. Which is the best MRI marker of malignancy for atypical cirrhotic nodules: Hypointensity in hepatobiliary phase alone or combined with other features? Classification after Gd-EOB-DTPA administration. Journal of Magnetic Resonance Imaging. 2012;36(3):648-657. doi:10.1002/jmri.23685
17. Phongkitkarun S, Limsamutpetch K, Tannaphai P, Jatchavala J. Added value of hepatobiliary phase gadoxetic acid-enhanced MRI for diagnosing hepatocellular carcinoma in high-risk patients. World Journal of Gastroenterology. 2013;19(45):8357-8365. doi:10.3748/wjg.v19.i45.8357
18. Kudo M, Matsui O, Izumi N, et al. JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 Update by the liver cancer study group of Japan. Liver Cancer. 2014;3(3-4):458-468. doi:10.1159/000343875
19. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis , Staging , and Management of Hepatocellular Carcinoma : 2018 Practice Guidance by the American Association for the Study of Liver Diseases. 2018;68(2):723-750. doi:10.1002/hep.29913
20. Galle PR, Forner A, Llovet JM, et al. Clinical Practice Guidelines OF HEPATOLOGY EASL Clinical Practice Guidelines : Management of hepatocellular carcinoma q. Journal of Hepatology. 2018;69(1):182-236. doi:10.1016/j.jhep.2018.03.019